NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Biocon Limited has completed a significant consolidation of its subsidiary, Biocon Biologics Limited (BBL), by acquiring shares from Mylan, Serum Institute, and other partners. The company allotted 17.13 crore equity shares at an issue price of Rs. 405.78 per share, resulting in an 11.36% equity dilution. Additionally, Biocon paid USD 200 million in cash to Mylan for a portion of the stake. Following these transactions, Biocon's ownership in its high-growth biologics arm has increased to approximately 94% on a fully diluted basis.
முக்கிய அம்சங்கள்
Allotted 17,12,79,553 equity shares at Rs. 405.78 per share on a preferential basis.Acquired 26.19 crore BBL shares via share swap and 7.18 crore BBL shares for USD 200 million cash.Biocon's total holding in Biocon Biologics Limited (BBL) increased to approximately 94%.Post-allotment, Mylan Inc. holds 6.10% and Serum Institute holds 3.68% in Biocon Limited.Total paid-up equity share capital increased from 133.70 crore to 150.82 crore shares.
👀 கவனிக்க வேண்டியவை
Investors should note the consolidation of the biologics business as a long-term positive for control and simplified structure, though they must account for the 11.36% equity dilution. Monitor the performance of Biocon Biologics as it now represents a much larger portion of the parent's value.
Biocon Completes Early Redemption of Rs 500 Crore NCDs
Biocon Limited has successfully completed the early full redemption of 50,000 unlisted, secured, rated, redeemable Non-Convertible Debentures (NCDs). The total value of the redemption amounts to Rs 500 Crores, with each NCD having a face value of Rs 1,00,000. The payment was executed on January 05, 2026, following Board approval granted in November 2025. This early repayment indicates a strong liquidity position and will likely reduce the company's future interest expenses.
முக்கிய அம்சங்கள்
Early full redemption of 50,000 unlisted, secured, rated NCDs completed.Total redemption amount aggregates to Rs 500 Crores.Face value per NCD was Rs 1,00,000, originally issued in May 2023.Payment completed on January 05, 2026, ahead of the January 31, 2026 target date.
👀 கவனிக்க வேண்டியவை
The early debt repayment is a positive indicator of Biocon's balance sheet strength and cash management. Investors should view this as a move to optimize capital structure and reduce interest costs.
Radio City to Redeem 89.7 Lakh NCRPS at ₹120 Per Share; Declares Interim Dividend
Music Broadcast Limited (Radio City) has approved the redemption of 89,69,597 Non-Convertible Redeemable Preference Shares (NCRPS) as their 36-month term concludes. Each NCRPS will be redeemed at ₹120, which includes the face value of ₹10, an issuance premium of ₹90, and a redemption premium of ₹20. Additionally, the board has declared an interim dividend of 0.1% (₹0.01 per share) on these preference shares for FY 2025-26. The record date for both the dividend and redemption proceeds is fixed as January 9, 2026.
முக்கிய அம்சங்கள்
Redemption of 89,69,597 NCRPS at a total value of ₹120 per share.Total redemption value includes a ₹20 per share premium over the issuance price.Interim dividend of ₹0.01 per NCRPS (0.1% of face value) declared for FY 2025-26.Record date for eligibility is January 9, 2026, with redemption scheduled for January 19, 2026.Total estimated cash outflow for the redemption is approximately ₹107.6 crore.
👀 கவனிக்க வேண்டியவை
Preference shareholders should ensure their holdings are in their demat accounts by January 9, 2026, to receive the ₹120 per share payout. Equity investors should note the impact of the ₹107.6 crore cash outflow on the company's cash reserves.
Biocon Shareholders Approve Fundraise and Preferential Share Issuance at EGM
Biocon Limited shareholders have approved all six resolutions proposed at the Extraordinary General Meeting held on December 31, 2025. Key approvals include raising funds through equity or other securities and a preferential issuance of shares for consideration other than cash. Shareholders also authorized an increase in investment and loan limits under Section 186 and cleared material related-party transactions with Mylan Inc. While most resolutions passed with near-unanimous support, the proposal to increase investment limits saw a notable 15.67% dissent from voting participants.
முக்கிய அம்சங்கள்
Approved raising funds in one or more tranches via equity or other securities with 99.13% majority support.Passed a special resolution for the issuance of equity shares on a preferential basis for non-cash consideration with 99.73% in favour.Authorized an increase in limits for investments, loans, and guarantees under Section 186 with 84.33% approval.Cleared material related-party transactions with Mylan Inc. with 99.19% of non-interested votes in favour.Total voting turnout for the meeting represented approximately 81% of the total share capital.
👀 கவனிக்க வேண்டியவை
Investors should monitor the upcoming details regarding the specific terms and pricing of the approved fundraise. The approval for preferential issuance and related-party transactions suggests strategic moves involving its subsidiary, Biocon Biologics.
Biocon EGM Approves Fundraise, Preferential Issue, and Mylan Related Party Transactions
Biocon Limited conducted an Extraordinary General Meeting on December 31, 2025, to pass six key resolutions focused on capital restructuring and growth. Shareholders voted on increasing the authorized share capital and raising fresh funds through equity or other securities in multiple tranches. A significant resolution involved the issuance of equity shares on a preferential basis for consideration other than cash, alongside approval for material related party transactions with Mylan Inc. These moves are designed to strengthen the balance sheet and support the strategic objectives of its subsidiary, Biocon Biologics.
முக்கிய அம்சங்கள்
Approval sought for increasing the Authorised Share Capital and amending the Memorandum of Association.Proposed raising of funds in one or more tranches through issuance of equity shares or other securities.Issuance of Equity Shares on a preferential basis for consideration other than cash.Approval for material related party transactions with Mylan Inc., a related party of Biocon Biologics.Increased limits for making investments, extending loans, and providing guarantees under Section 186.
👀 கவனிக்க வேண்டியவை
Investors should monitor the specific terms of the fundraise and the identity of the preferential allottees to assess potential dilution. The non-cash preferential issue and Mylan transaction suggest a strategic settlement or asset acquisition that could impact long-term valuation.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Biocon Biologics Secures Full Global Rights for Biosimilar Adalimumab (Hulio)
Biocon Biologics has expanded its agreement with Fujifilm Kyowa Kirin Biologics (FKB) to secure full and exclusive global rights for Hulio (biosimilar Adalimumab). This strategic move transitions Biocon from a commercialization-only partner to an end-to-end owner responsible for manufacturing, development, and commercialization. While Biocon will pay license fees and royalties, FKB will offset certain development costs, which is expected to enhance cost efficiency and operational flexibility. This integration strengthens Biocon's immunology portfolio, which currently serves over 6.3 million patients across 120+ countries.
முக்கிய அம்சங்கள்
Acquisition of full global rights for manufacturing and commercialization of biosimilar Adalimumab (Hulio).Transition from a commercialization-only model to an end-to-end integrated model for the product.FKB to offset certain development costs while Biocon pays technology license fees and royalties.Strategic focus on the immunology portfolio, which currently includes three major biosimilars.Commercial production at Biocon facilities to commence following technology transfer and regulatory approvals.
👀 கவனிக்க வேண்டியவை
This vertical integration is a margin-accretive move that provides Biocon with greater control over its supply chain and product development. Investors should monitor the timeline for technology transfer and regulatory approvals for the in-house manufacturing of Hulio.
Biocon Limited has successfully issued Commercial Papers (CP) worth Rs 1,800 Crores on a private placement basis. The short-term debt instrument carries a competitive interest rate of 6.85% and has a tenure of 88 days, maturing on March 20, 2026. The issue has been subscribed by major institutional investors including SBI Mutual Fund, Axis Mutual Fund, and Aditya Birla Sun Life. The high credit rating of IND A1+ underscores the company's strong short-term credit profile.
முக்கிய அம்சங்கள்
Total issue size of Rs 1,800 Crores via private placement to mutual fundsShort-term tenure of 88 days with maturity scheduled for March 20, 2026Competitive coupon rate of 6.85% per annumAssigned a top-tier credit rating of IND A1+ by India RatingsProposed to be listed on the National Stock Exchange (NSE)
👀 கவனிக்க வேண்டியவை
Investors should view this as a routine short-term liquidity management exercise. The low interest rate and high credit rating indicate strong market confidence in Biocon's financial stability.
KIOCL Credit Rating Downgraded to BWR A- and Withdrawn Following ₹205 Cr FY25 Net Loss
Brickwork Ratings has downgraded KIOCL's long-term rating to BWR A- (Negative) and short-term rating to BWR A2, subsequently withdrawing them at the company's request. The downgrade follows a significant 68% decline in FY25 revenue to ₹590 crore and a widening net loss of ₹205 crore due to prolonged operational shutdowns. While the company has repaid its fund-based limits and remains debt-free, the negative outlook reflects continued volatility and recurring losses. However, liquidity remains a strength with cash reserves of ₹690 crore as of H1 FY26.
முக்கிய அம்சங்கள்
FY25 revenue plummeted 68% YoY to ₹590 crore from ₹1,858 crore in FY24Net loss widened significantly to ₹205 crore in FY25 compared to ₹83 crore in the previous yearLong-term rating downgraded from BWR A to BWR A- with a Negative outlook prior to withdrawalCompany maintains a debt-free status with a healthy cash balance of ₹690 crore as of H1 FY26Operations were severely impacted by a 232-day shutdown and a sharp drop in export volumes to 0.15 MTPA
👀 கவனிக்க வேண்டியவை
Investors should exercise caution as the rating downgrade highlights structural cost imbalances and sustained operating losses. The primary catalyst for a potential turnaround is the operationalization of the Devadari iron ore mine to secure captive raw materials.
Biocon Receives US FDA EIR with VAI Status for New Jersey Generics Facility
Biocon Limited has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (US FDA) for its Biocon Generics Inc facility in Cranbury, New Jersey. The inspection, which took place from October 6 to October 10, 2025, resulted in a 'Voluntary Action Indicated' (VAI) status. A VAI status indicates that while some objectionable conditions were observed, the agency is not recommending any administrative or regulatory action at this time. This outcome is positive as it signifies the facility is in a state of acceptable compliance for the U.S. market.
முக்கிய அம்சங்கள்
US FDA issued an Establishment Inspection Report (EIR) for the Cranbury, New Jersey facility.The inspection was conducted over a 5-day period from October 6 to October 10, 2025.The facility received a 'Voluntary Action Indicated' (VAI) classification, avoiding more severe regulatory sanctions.The EIR marks the formal closure of the inspection cycle for this specific U.S.-based manufacturing site.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive regulatory development that reduces compliance risk for Biocon's U.S. operations. This clearance supports the company's ability to maintain supply and seek new product approvals from this facility.
Biocon Retains [ICRA]AA+ Rating; To Acquire BBL Minority Stakes for $1.17 Billion
ICRA has reaffirmed Biocon's credit rating at [ICRA]AA+ (Stable) following the company's announcement to acquire remaining minority stakes in Biocon Biologics (BBL) for $1.17 billion. The transaction involves a $773 million share swap and a $400 million cash payment, making BBL a wholly-owned subsidiary. To fund the cash component and repay existing structured debt, Biocon plans a QIP of up to Rs. 4,500 crore. This restructuring aims to simplify the group's corporate structure and consolidate BBL, which contributed 58% of consolidated revenues in FY2025.
முக்கிய அம்சங்கள்
ICRA reaffirmed [ICRA]AA+ (Stable) and [ICRA]A1+ ratings for Rs. 450 crore unallocated instruments.Acquisition of minority stakes in BBL valued at $1.17 billion from Mylan, Serum Institute, and others.Funding includes a share swap of 171.3 million shares and $400 million cash funded via CP and a Rs. 4,500 crore QIP.BBL is the largest revenue contributor, accounting for 58% of Biocon's consolidated revenue in FY2025.Structured debt from the Viatris acquisition is scheduled to be repaid by January 31, 2026, using QIP proceeds.
👀 கவனிக்க வேண்டியவை
Investors should monitor the successful execution and pricing of the Rs. 4,500 crore QIP, as it is critical for the company's deleveraging and the BBL consolidation. The move is a long-term positive as it simplifies the corporate structure and eliminates the holding company discount.
ICRA Reaffirms Biocon's AA+ Rating; Highlights $1.17B Biocon Biologics Consolidation
ICRA has reaffirmed Biocon's credit rating at [ICRA]AA+ (Stable) following the company's announcement to acquire the remaining minority stakes in Biocon Biologics (BBL) for $1.17 billion. The transaction involves a $773 million share swap and a $400 million cash component, funded through Commercial Paper and a proposed Rs. 4,500 crore QIP. This move simplifies the group structure, making BBL—which accounts for 58% of FY25 revenues—a wholly-owned subsidiary. While consolidated leverage is expected to reduce after repaying structured debt by January 2026, the successful execution of the QIP remains a key monitorable factor.
முக்கிய அம்சங்கள்
ICRA reaffirmed [ICRA]AA+ (Stable) and [ICRA]A1+ ratings for Rs. 450 crore unallocated limits.Biocon to acquire minority stakes in Biocon Biologics for $1.17 billion, making it a 100% subsidiary.Funding includes a Rs. 6,950 crore share swap and a $400 million cash payment.Company plans a QIP of up to Rs. 4,500 crore to repay bridge financing and structured debt by Jan 2026.Biocon Biologics is the largest revenue contributor, accounting for 58% of consolidated FY25 revenue.
👀 கவனிக்க வேண்டியவை
Investors should monitor the successful completion of the Rs. 4,500 crore QIP as it is crucial for deleveraging the balance sheet. The consolidation of the biologics business is a strategic positive that eliminates holding company discounts and simplifies the corporate structure.
Biocon launches Liraglutide (gVictoza®) in Netherlands
Biocon Limited has launched its Glucagon-like Peptide-1 (GLP -1), Liraglutide, in the Netherlands through its distribution partner Pharmamedic B.V. The drug-device combination will be marketed under the brand names Diavorin® for diabetes and Vobexoryn® for chronic weight management. This launch marks the first country in the European Union where Biocon will directly launch Liraglutide under its own brand. Liraglutide was approved for medical use in the European Union in 2009.
முக்கிய அம்சங்கள்
Biocon launched Liraglutide in the Netherlands on December 15, 2025.Liraglutide will be marketed as Diavorin® for diabetes.Liraglutide will be marketed as Vobexoryn® for chronic weight management.Liraglutide was approved for medical use in the European Union in 2009.
👀 கவனிக்க வேண்டியவை
This launch in the Netherlands is a positive step for Biocon, indicating expansion in the European market; investors should monitor the sales performance of Diavorin® and Vobexoryn® in the coming quarters.
Biocon Biologics to Commercialize Biosimilar Aflibercept Worldwide
Biocon Biologics has signed a settlement and license agreement to commercialize biosimilar Aflibercept (YESAFILI) worldwide. This agreement with Regeneron and Bayer covers Europe and the rest of the world, following a previous settlement for the US and Canada. YESAFILI is a VEGF inhibitor used for ophthalmology conditions. The company plans to launch YESAFILI in the UK in January 2026 and in other settled countries by March 2026 or earlier.
முக்கிய அம்சங்கள்
Biocon Biologics will commercialize biosimilar Aflibercept (40mg/ml) worldwide.YESAFILI launch in the United Kingdom is planned for January 2026.YESAFILI launch in other settled countries is planned for March 2026 or earlier.Biocon Biologics has commercialized 10 biosimilars across 120+ countries.
👀 கவனிக்க வேண்டியவை
This agreement expands Biocon Biologics' global presence in the ophthalmology therapeutic area. Investors should monitor the launch and market uptake of YESAFILI in 2026.
IOC Declares Rs 5 Interim Dividend for FY 2025-26; Sets Record Date for Dec 18
Indian Oil Corporation (IOC) has declared an interim dividend of Rs 5 per share for the financial year 2025-26. The company has fixed December 18, 2025, as the record date to determine shareholder eligibility for the payout. Tax will be deducted at source (TDS) at a rate of 10% for resident shareholders with a valid PAN, provided the total dividend for the year exceeds Rs 10,000. Shareholders must submit necessary tax exemption documents like Form 15G/15H by December 17, 2025, to avoid higher tax deductions.
முக்கிய அம்சங்கள்
Interim dividend of Rs 5 per equity share declared for the financial year 2025-26.Record date for determining dividend entitlement is set for December 18, 2025.TDS of 10% applicable for residents with PAN; 20% for those without or with invalid PAN.The Rs 10,000 TDS threshold includes the final dividend for 2024-25 paid in September 2025.Deadline for submitting tax-related documents (Form 15G/15H/10F) is December 17, 2025.
👀 கவனிக்க வேண்டியவை
Investors should ensure their PAN is correctly linked to their demat accounts and submit Form 15G/15H by Dec 17 if they qualify for tax exemptions. Non-resident investors should provide Tax Residency Certificates and Form 10F to avail beneficial DTAA rates.
Indian Oil Corporation Limited (IOC) has announced an interim dividend of ₹5.00 per equity share with a face value of ₹10 each for the financial year 2025-26. This dividend represents 50% of the face value. The payment will be made on or before January 11, 2026, to eligible shareholders. The record date for determining eligibility is December 18, 2025.
முக்கிய அம்சங்கள்
Interim dividend declared: ₹5.00 per equity shareFace value of equity share: ₹10Dividend is 50% of face valueRecord date: December 18, 2025Payment date on or before: January 11, 2026
👀 கவனிக்க வேண்டியவை
Shareholders should note the record date of December 18, 2025, to ensure eligibility for the interim dividend. Consider holding the stock to receive the dividend if it aligns with your investment strategy.
RADIOCITY: Madras HC sets aside contempt orders; no financial impact
Music Broadcast Limited (RADIOCITY) announced that the Madras High Court allowed the company's appeals and set aside prior orders related to contempt petitions. The court's decision eliminates the requirement to deposit 50% of alleged royalty dues and furnish historical music-play logs. The High Court held that contempt jurisdiction was not maintainable, as the underlying order is under consideration by the Supreme Court and the monetary liability is unquantified. Consequently, the company anticipates no financial impact from the overturned contempt orders.
முக்கிய அம்சங்கள்
Madras High Court allowed letters patent appeals on December 10, 2025Orders dated July 31, 2024 and August 26, 2025 in contempt petitions set asideNo obligation to deposit 50% of alleged royalty duesNo financial impact on the Company from the impugned contempt orders
👀 கவனிக்க வேண்டியவை
The positive ruling removes a potential financial burden. Investors can view this as a favorable development, reducing uncertainty related to legal proceedings.
S&P Global Places Biocon Biologics on Positive CreditWatch; Debt to Drop to ₹120 Billion
S&P Global Ratings has placed Biocon Biologics on 'CreditWatch Positive' following a major restructuring plan to make it a 100% subsidiary of Biocon Limited. The company aims to reduce its adjusted debt significantly from INR 248 billion in March 2025 to approximately INR 120 billion by March 2026. This reduction will be driven by swapping $1 billion in debt-like CCPS held by Viatris for equity and cash, alongside a planned INR 45 billion fresh equity issuance. The move simplifies the capital structure and eliminates minority put options that were previously viewed as debt-like obligations.
முக்கிய அம்சங்கள்
S&P Global placed 'BB' rating on CreditWatch Positive, signaling a potential upgrade within 60-90 days.Adjusted debt is projected to fall by over 50% to INR 120 billion by the end of FY26.Biocon to acquire the remaining 25% stake in Biocon Biologics from minority investors including Viatris and Serum Institute.Viatris' $1 billion CCPS will be settled through $415 million in Biocon equity and $400 million in cash.The cash component for the transaction is intended to be funded via a fresh INR 45 billion equity raise.
👀 கவனிக்க வேண்டியவை
Investors should view this as a major positive for the balance sheet as it significantly reduces leverage and simplifies the corporate structure. Key monitorables include the successful execution of the INR 45 billion equity fundraise and the final resolution of the CreditWatch by S&P.
India Ratings has assigned 'IND AA+/Stable/IND A1+' to Biocon's bank loan facilities of INR 5,500 million and 'IND A1+' to proposed commercial paper of INR 8,000 million. The agency has also affirmed 'IND AA+/Stable/ IND A1+' for existing bank loan facilities of INR 4,500 million and 'IND A1+' for proposed commercial paper of INR 12,000 million. The rating on non-convertible debentures of INR 10,700 million has been withdrawn as the instrument has been paid in full. These ratings reflect India Ratings' assessment of Biocon's creditworthiness.
முக்கிய அம்சங்கள்
INR 5,500 million bank loan facilities assigned IND AA+/Stable/IND A1+ ratingINR 8,000 million proposed commercial paper assigned IND A1+ ratingINR 4,500 million bank loan facilities affirmed at IND AA+/Stable/ IND A1+INR 12,000 million proposed commercial paper affirmed at IND A1+INR 10,700 million non convertible debenture rating withdrawn
👀 கவனிக்க வேண்டியவை
Investors should monitor Biocon's debt levels and credit ratings for any changes. The affirmed and assigned ratings indicate a stable outlook for the company's debt obligations.
Biocon to Consolidate 100% Stake in Biocon Biologics via $1.17 Billion Deal
Biocon Limited has announced a major consolidation plan to acquire the remaining 23.3% minority stake in Biocon Biologics, making it a 100% subsidiary. The transaction involves a $773 million share swap (171.3 million shares at ₹405.78 each) and a $400 million cash payment to Viatris. This move is designed to simplify the corporate structure, eliminate the holding company discount, and improve financial metrics, with a proforma Net Debt/EBITDA ratio of 2.5x. The company expects the transaction to be completed by Q4 FY2026, following a shareholder vote on December 31, 2025.
முக்கிய அம்சங்கள்
Acquisition of 23.3% minority stake from Viatris, Serum Institute, Tata Capital, and True North.Total consideration includes $773M in equity shares and $400M in cash funded via QIP or bridge loans.Consolidation expected to generate annual interest savings of ₹300 crore.Proforma Net Debt/EBITDA reduced to 2.5x from 4.3x in FY23 through deleveraging and EBITDA growth.Targeting transaction completion by Q4 FY2026 with a long-stop date of March 31, 2026.
👀 கவனிக்க வேண்டியவை
Investors should look favorably on this consolidation as it simplifies the group structure and removes the holding company discount. Monitor the upcoming EGM on December 31 and the successful execution of the $400M cash funding through a QIP or rights issue.
Biocon to Issue 17.13 Cr Shares at ₹405.78 and Raise Investment Limits to ₹20,000 Cr
Biocon has convened an Extra-Ordinary General Meeting (EGM) on December 31, 2025, to seek approval for significant capital restructuring. The company proposes to issue up to 17,12,79,553 equity shares on a preferential basis at ₹405.78 per share for consideration other than cash. Additionally, it seeks to increase its authorized share capital to ₹900 crore and significantly expand its investment and loan limits under Section 186 to ₹20,000 crore. These moves suggest a major upcoming acquisition or strategic asset integration.
முக்கிய அம்சங்கள்
Preferential issuance of up to 17.13 crore equity shares at a fixed price of ₹405.78 per shareProposed increase in Authorized Share Capital from ₹700 crore to ₹900 croreExpansion of Section 186 limits for loans, guarantees, and investments to ₹20,000 croreThe share issuance is for 'consideration other than cash', indicating a potential swap or acquisitionEGM scheduled for December 31, 2025, with a voting cut-off date of December 24, 2025
👀 கவனிக்க வேண்டியவை
Investors should closely monitor the specific details of the asset or entity being acquired in exchange for the 17.13 crore shares, as this represents significant equity dilution. The pricing of ₹405.78 serves as a key valuation benchmark for the stock in the near term.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
